2019 CYIR Finalized

33 2. Few patients in the lower tidal volume strategy achieved target tidal volume; most were managed with pressure support by day 1. 3. Separation of median tidal volumes between randomization arms decreased quickly, beginning at 4.2 cc/kg PBW on day 0, and decreasing to 2.7 cc/kg PBW on day 1 and 2 cc/kg PBW on day 2. 4. There was no difference in ventilator-free days, mortality or development of ARDS between randomization arms. 5. It remains unclear if there is a benefit to managing patients without ARDS with lower versus intermediate tidal volumes; a recent study by the NHLBI PETAL Network (Lanspa et al) sug- gests that the mortality benefit may be small and therefore an appropriately powered trial would need to be very large and likely unfeasible. RAPIDLY IMPROVING ARDS Schenck EJ, Oromendia C, Torres LK, Berlin DA, Choi AMK, Siempos II. Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. Chest 2019; 155(3):474- 482 Summary ARDS is recognized as a highly heterogeneous clinical syndrome. This heterogeneity is a challenge to clinical trials attempting to identify beneficial treatment. Indeed, the vast majority of trials—especially pharmacologic trials—have failed to demonstrate benefit. Identification of subgroups with increased risk of specific clinical outcomes (prognos- tic enrichment) or with increased likelihood of response to therapy (predictive enrichment) may be an important strategy to improving future trials. Similarly, identification of groups unlikely to benefit from a particular therapy may be similarly important. Schenck and colleagues propose that there is a phenotype of rapidly improving ARDS (defined as improving within 24 hours to either extubation or PaO2:FIO2 ratio > 300) which is at low risk for adverse outcomes and unlikely to benefit from intervention. In a secondary analysis of 7 ARDS Network studies, 458 of 4,361 patients (10.5%) met criteria for rapidly improving ARDS (riARDS), and that the proportion of riARDS patients in ARDS Network tri- als increased over time. Schenck found that patients with riARDS had a significantly lower hospital mortality (10.2% compared with 26.3%) and could be identified by factors present at study enrollment. Future interventional studies of patients with ARDS might consider excluding patients with this rapidly improving phenotype. Comments 1. A significant proportion of patients enrolled in ARDS Network trials improve rapidly, achieving extubation or resolution of sig- nificant hypoxemia within 24 hours. 2. Patients with this “rapidly improving” phenotype have a mark- edly lower mortality than those without rapid improvement. 3. While there are a number of factors independently associated with riARDS (PaO2:FIO2 ratio at screening, change in between screening and enrollment, number of vasopressors used, FIO2, and bilirubin), the model has a low positive predictive value. 4. Future clinical trials may attempt to exclude patients with riARDS, but may find challenges if enrollment window is short. OTHER ARTICLES OF INTEREST Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Juni P, Brodie D, Slutsky AS, Combes A. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial. JAMA 2018; 320(21): 2251-2259 Munshi L, Walkey A, Goligher E, Pham T, Uleryk EM, Fan E. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respiratory Medicine 2019; 7:163-72 Lanspa MJ, Gong MN, Schoenfeld DA, Lee KT, Grissom CK, Hou PC, Serpa-Neto A, Brown SM, Iwashyna TJ, Yealy DM, Hough CL, Brower RG, Calfee CS, Hyzy RC, Matthay MA, Miller RR 3rd, Steingrub JS, Thompson BT, Miller CD, Clemmer TP, Hendey GW, Huang DT, Mathews KS, Qadir N, Tidswell M; The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network. Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure. Annals of the American Thorac Society. 2019 Mar;16(3):356-362 ARDS

RkJQdWJsaXNoZXIy MTM1ODMw